StreetInsider.com News Articles

Cantor Fitzgerald Reiterates Overweight Rating on Tenax Therapeutics (TENX)

Thu, 10 Sep 2026 09:24:16 -0400

Cantor Fitzgerald analyst Olivia Brayer Saunders reiterated an Overweight rating and $35.00 price target on Tenax Therapeutics (NASDAQ: TENX).

The analyst commented, "The key question is: does levosimendan still have a path forward in PHHFpEF? TENX certainly thinks so: We had a chance to chat with TENX's CEO this morning in our Cantor HC Conference Fireside Chat just after they released the new slides/analysis. Yes, LEVEL missed its primary endpoint - but TENX is making the case that this drug is doing exactly what the company hoped it would. It's just a matter of using it in the right patients. Our

Guggenheim Downgrades Tenax Therapeutics (TENX) to Neutral

Mon, 31 Aug 2026 06:09:22 -0400

Guggenheim analyst Seamus Fernandez downgraded Tenax Therapeutics (NASDAQ: TENX) from Buy to Neutral.

For an analyst ratings summary and ratings history on Tenax Therapeutics click here. For more ratings news on Tenax Therapeutics click here.

Shares of Tenax Therapeutics closed at $2.13 yesterday.

Tenax shares Phase 3 LEVEL trial data at ESC Congress 2026

Sat, 29 Aug 2026 08:21:40 -0400

Tenax Therapeutics (Nasdaq: TENX) presented additional results from its Phase 3 LEVEL clinical trial of TNX-103 (oral levosimendan) at the European Society of Cardiology Congress 2026 in Munich, Germany, according to a company statement.

The trial enrolled 241 patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) across 41 sites in the United States and Canada. The primary endpoint — change in six-minute walk distance (6MWD) at Week 12 — did not achieve statistical significance across the overall trial population, nor did the key secondary endpoint measuring symptom scores.

In a prespecified subgroup of patients with a baseline

Tenax shares Phase 3 LEVEL trial data at ESC Congress 2026

Sat, 29 Aug 2026 08:21:40 -0400

In a prespecified subgroup of patients with a baseline

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Sat, 29 Aug 2026 08:21:00 -0400

In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112)

In the same patient population, TNX-103 produced a 47% reduction in NT-proBNP (p < 0.0001) and a 4.9 mmHg reduction in RVSP (p = 0.009) compared to placebo

With full statistics analysis now complete, Company confirms TNX-103’s biological effects include marked reductions in pulmonary artery pressure and NT-proBNP, a biomarker reflecting increased cardiac wall stress. Results will inform protocol population enrichment and changes to overall registrational path

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Sat, 29 Aug 2026 08:21:00 -0400

In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112)

In the same patient population, TNX-103 produced a 47% reduction in NT-proBNP (p < 0.0001) and a 4.9 mmHg reduction in RVSP (p = 0.009) compared to placebo

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Sat, 29 Aug 2026 08:21:00 -0400

In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112)

In the same patient population, TNX-103 produced a 47% reduction in NT-proBNP (p < 0.0001) and a 4.9 mmHg reduction in RVSP (p = 0.009) compared to placebo

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Sat, 29 Aug 2026 08:21:00 -0400

In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112)

In the same patient population, TNX-103 produced a 47% reduction in NT-proBNP (p < 0.0001) and a 4.9 mmHg reduction in RVSP (p = 0.009) compared to placebo

Form SCHEDULE 13G TENAX THERAPEUTICS, INC. Filed by: ING GROEP NV

Thu, 27 Aug 2026 20:22:00 -0400

si-local-file:///var/storage/secattach/20260827/26991755.html

Form SCHEDULE 13G TENAX THERAPEUTICS, INC. Filed by: ING GROEP NV

Thu, 27 Aug 2026 20:22:00 -0400

si-local-file:///var/storage/secattach/20260827/26991755.html

Form SCHEDULE 13G TENAX THERAPEUTICS, INC. Filed by: SPHERA FUNDS MANAGEMENT LTD.

Thu, 27 Aug 2026 06:20:00 -0400

si-local-file:///var/storage/secattach/20260827/26984275.html

Form SCHEDULE 13G TENAX THERAPEUTICS, INC. Filed by: SPHERA FUNDS MANAGEMENT LTD.

Thu, 27 Aug 2026 06:20:00 -0400

si-local-file:///var/storage/secattach/20260827/26984275.html

Form 4 TENAX THERAPEUTICS, INC. For: Aug 20 Filed by: Schneeberger Daniel

Mon, 24 Aug 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260824/26969375.html

Form 4 TENAX THERAPEUTICS, INC. For: Aug 20 Filed by: Schneeberger Daniel

Mon, 24 Aug 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260824/26969375.html

Form 3 TENAX THERAPEUTICS, INC. For: Aug 20 Filed by: Schneeberger Daniel

Mon, 24 Aug 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260824/26969333.html

Form 3 TENAX THERAPEUTICS, INC. For: Aug 20 Filed by: Schneeberger Daniel

Mon, 24 Aug 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260824/26969333.html

Form SCHEDULE 13G TENAX THERAPEUTICS, INC. Filed by: MILLENNIUM MANAGEMENT LLC

Tue, 18 Aug 2026 19:09:00 -0400

si-local-file:///var/storage/secattach/20260818/26945905.html

Form SCHEDULE 13G TENAX THERAPEUTICS, INC. Filed by: MILLENNIUM MANAGEMENT LLC

Tue, 18 Aug 2026 19:09:00 -0400

si-local-file:///var/storage/secattach/20260818/26945905.html

Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Ikarian Capital, LLC

Fri, 14 Aug 2026 21:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26933304.html

Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Ikarian Capital, LLC

Fri, 14 Aug 2026 21:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26933304.html

Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26932879.html

Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26932879.html

Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260814/26932327.html

Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260814/26932327.html

Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: BIOTECHNOLOGY VALUE FUND L P

Fri, 14 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260814/26931372.html